Tuesday, March 5, 2024 Semaglutide Reduces Severity of Common Liver Disease in People with HIV Transmission electron micrograph of HIV-1 virus particles (yellow) replicating from the plasma membrane of an H9 T cell (purple and pink). Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and metabolic dysfunction-associated steatotic liver disease, a common form of liver disease, according to a NIAID-sponsored study presented today at the 2024 Conference on Retroviruses and Opportunistic Infections. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107